Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Buy
69
CDNA Quote, Financials, Valuation and Earnings
Last price:
$19.71
Seasonality move
:
34.47%
Day range:
$19.17 - $19.91
52-week range:
$13.18 - $34.84
Dividend yield:
0%
P/E ratio:
17.15x
P/S ratio:
3.27x
P/B ratio:
2.89x
Volume:
715.8K
Avg. volume:
1.4M
1-year change:
29.65%
Market cap:
$1.1B
Revenue:
$333.8M
EPS (TTM):
$1.15
Analysts' Opinion
-
Consensus RatingCareDx has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.29, CareDx has an estimated upside of 48.51% from its current price of $19.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.00 representing 100% downside risk from its current price of $19.72.
Fair Value
-
According to the consensus of 7 analysts, CareDx has 48.51% upside to fair value with a price target of $29.29 per share.
CDNA vs. S&P 500
-
Over the past 5 trading days, CareDx has overperformed the S&P 500 by 14.78% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
CareDx does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CareDx has grown year-over-year revenues for 4 quarters straight. In the most recent quarter CareDx reported revenues of $84.7M.
Earnings Growth
-
CareDx has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CareDx reported earnings per share of -$0.19.
Enterprise value:
867.1M
EV / Invested capital:
2.29x
Price / LTM sales:
3.27x
EV / EBIT:
--
EV / Revenue:
2.50x
PEG ratio (5yr expected):
-0.13x
EV / Free cash flow:
43.03x
Price / Operating cash flow:
56.29x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$234.3M
Return On Assets:
12.38%
Net Income Margin (TTM):
16.99%
Return On Equity:
18.96%
Return On Invested Capital:
18.96%
Operating Margin:
-9.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $319.6M | $275.1M | $346.4M | $72M | $84.7M | |
| Gross Profit | $208.3M | $173.1M | $234.3M | $46.1M | $56.3M | |
| Operating Income | -$82.5M | -$103M | -$42.4M | -$22.6M | -$8M | |
| EBITDA | -$65.3M | -$82.7M | -$23M | -$17.3M | -$3.1M | |
| Diluted EPS | -$1.51 | -$3.47 | $1.15 | -$0.38 | -$0.19 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $438.7M | $411.5M | $371.4M | $303.1M | $350.2M | |
| Total Assets | $541.2M | $546.7M | $528.2M | $452.4M | $489.6M | |
| Current Liabilities | $45.7M | $66.9M | $71.8M | $70.2M | $85.3M | |
| Total Liabilities | $69.7M | $89.2M | $108.2M | $196.2M | $110.3M | |
| Total Equity | $471.5M | $457.5M | $420M | $256.2M | $379.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.1M | -$34.4M | $26.8M | -$15.3M | -$26.6M | |
| Cash From Investing | -$87.2M | $82.9M | -$26.8M | $27.7M | $1.3M | |
| Cash From Financing | -$6.5M | -$29.7M | -$5M | -$1.3M | -$643K | |
| Free Cash Flow | -$21.6M | -$42.3M | $20.1M | -$16.8M | -$28.2M | |
CDNA
Sector
Market Cap
$1.1B
$33.8M
Price % of 52-Week High
56.6%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
29.65%
-37.45%
Beta (5-Year)
2.180
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$18.17
200-day SMA
Sell
Level
$22.74
Bollinger Bands (100)
Buy
Level
16.74 - 22.22
Chaikin Money Flow
Buy
Level
24.4M
20-day SMA
Buy
Level
$17.46
Relative Strength Index (RSI14)
Buy
Level
64.92
ADX Line
Buy
Level
16.74
Williams %R
Sell
Level
-5.15
50-day SMA
Buy
Level
$17.37
MACD (12, 26)
Buy
Level
0.53
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
84.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.4221)
Buy
CA Score
(Annual)
Level (0.0733)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-5.2721)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Stock Forecast FAQ
In the current month, CDNA has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CDNA average analyst price target in the past 3 months is $29.29.
-
Where Will CareDx Stock Be In 1 Year?
According to analysts, the consensus estimate is that CareDx share price will rise to $29.29 per share over the next 12 months.
-
What Do Analysts Say About CareDx?
Analysts are divided on their view about CareDx share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CareDx is a Sell and believe this share price will drop from its current level to $19.00.
-
What Is CareDx's Price Target?
The price target for CareDx over the next 1-year time period is forecast to be $29.29 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CDNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CareDx is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CDNA?
You can purchase shares of CareDx via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CareDx shares.
-
What Is The CareDx Share Price Today?
CareDx was last trading at $19.71 per share. This represents the most recent stock quote for CareDx. Yesterday, CareDx closed at $19.72 per share.
-
How To Buy CareDx Stock Online?
In order to purchase CareDx stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Exxon Stock Be in 5 Years?
For sure Exxon Mobil (NYSE: XOM) is no hyped-up AI…
How High Will Dollar General Stock Go?
Shares of Dollar General (NYSE:DG) have risen significantly in recent…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
64
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
59
SBET alert for Jun 10
SharpLink Gaming [SBET] is up 10.98% over the past day.
Buy
85
ASTS alert for Jun 10
AST SpaceMobile [ASTS] is up 3.36% over the past day.
Buy
69
CCJ alert for Jun 10
Cameco [CCJ] is down 4.59% over the past day.
